Congress Should Open CBD Door, Close VMS Market Holes – Sharfstein, Cohen
"We seem to be headed toward a confusing, uneven, and potentially risky market in CBD products. This situation creates an opportunity for Congress to take action," say Joshua Sharfstein and Pieter Cohen in NEJM. Additionally, GW Pharma exec says FDA should reign in the "unfettered" production and sales of food and supplements containing CBD , hemp or other cannabis-based ingredients to prevent potential harm to consumers.
You may also be interested in...
US Wellness Market In 2019: Amarin Wins, Loses On Supplements; Gottlieb Leaves With Consumer Health Flourish
US Wellness Market In 2019: Farm Bill Made Cultivating Cannabidiol Policy FDA's Main Course In Supplements
As HBW Insight looks back on notable US wellness market developments and events for the previous 12 months, we find that news in the CBD space from the FDA and the industry dominated the sector throughout 2019.
The agency announces that it cannot conclude cannabidiol is GRAS, potentially heading off GRAS notifications and making NDI notifications a likelier future for CBD use in the supplement sector if any “lawful pathway” is to be found. In addition to a barrage of warning letters to marketers of CBD products, the FDA issued a stark warning to consumers about potential hazards.